Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Antitope, UCL ink research and license agreement
October 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

CAMBRIDGE, U.K.—Antitope Ltd., an Abzena company, and University College London (UCL) will be collaborating to humanize an anti-LRG1 antibody as part of an MRC-funded translational research and product development program by the UCL Institute of Ophthalmology. UCL Business PLC, UCL’s wholly owned technology transfer company, will be supporting the collaboration, having provided initial proof-of-concept funding and holding the LRG1 technology patents. Antitope will use its Composite Human Antibody technology to generate a range of fully humanized antibodies designed to bind to and inhibit the function of LRG1, and UCL will select a lead antibody for further investigation as a potential treatment for age-related macular degeneration.
 
“LRG1 is a highly promising target for controlling pathogenic angiogenesis, and we are excited to be working with Antitope to develop an anti-LRG1 antibody as a potential therapeutic agent,” said Prof. Stephen Moss, UCL Ashton Professor of Biomedical Research and vice-dean Enterprise.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.